CG
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Alerte au feu : des nanopompiers pour combattre les flammes de la polyarthrite rhumatoïde | Revue médicale suisse | 2024 | 66 | 4 | |||
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | 2024 | 44 | 12 | |||
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | 2024 | 20 | 6 | |||
IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome | The Journal of immunology | 2023 | 80 | 49 | |||
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | 2023 | 62 | 24 | |||
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational Study | Arthritis care & research | 2023 | 15 | 6 | |||
Special Issue “IL-1 family cytokines in host defense, inflammation and cancer” | Cytokine | 2022 | 141 | 71 | |||
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls | Vaccine | 2022 | 22 | 0 | |||
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling | Arthritis & rheumatology | 2022 | 52 | 21 | |||
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints | Cytokine | 2022 | 121 | 77 | |||
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis | Rheumatology | 2021 | 305 | 287 | |||
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | 2021 | 183 | 0 | |||
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers | Arthritis and Rheumatology | 2021 | 119 | 210 | |||
Intracellular IL-1 receptor antagonist isoform 1 released from keratinocytes upon cell death acts as an inhibitor for the alarmin IL-1α | Journal of Immunology | 2020 | 289 | 2 | |||
Response to: 'When binary and continuous responses disagree' by Dr Ouyang | Annals of the Rheumatic Diseases | 2020 | 273 | 2 | |||
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools | Clinical and Experimental Rheumatology | 2020 | 200 | 59 | |||
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis | Arthritis Research and Therapy | 2020 | 352 | 87 | |||
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis | Life Science Alliance | 2020 | 134 | 354 | |||
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies | Rheumatology International | 2020 | 161 | 38 | |||
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva Cocktail | Clinical Pharmacology and Therapeutics | 2020 | 256 | 290 | |||
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities | RMD Open | 2020 | 91 | 31 | |||
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome | Rheumatology | 2020 | 223 | 0 | |||
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial | The Lancet | 2020 | 194 | 0 | |||
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications† | Biology of Reproduction | 2020 | 92 | 0 | |||
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome | Rheumatology | 2020 | 266 | 1 | |||
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation Syndrome | Journal of Immunology | 2020 | 221 | 1 | |||
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform | Orphanet Journal of Rare Diseases | 2020 | 107 | 80 | |||
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes | Arthritis Research and Therapy | 2020 | 106 | 51 | |||
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland | RMD Open | 2020 | 129 | 55 | |||
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease | Rheumatology | 2020 | 249 | 8 | |||
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study | Travel Medicine and Infectious Disease | 2020 | 109 | 0 | |||
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab | Advances in Rheumatology | 2019 | 228 | 108 | |||
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | 2019 | 300 | 0 | |||
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study | Rheumatology | 2019 | 252 | 0 | |||
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis | British Journal of Haematology | 2019 | 196 | 0 | |||
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort | Rheumatology | 2019 | 226 | 0 | |||
Long-term therapy with anakinra in hidradenitis suppurativa in three patients | International Journal of Dermatology | 2019 | 250 | 1 | |||
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions | Seminars in Arthritis and Rheumatism | 2019 | 229 | 0 | |||
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis | RMD Open | 2019 | 269 | 70 | |||
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis | Seminars in Arthritis and Rheumatism | 2019 | 259 | 133 | |||
Prevotella copri in individuals at risk for rheumatoid arthritis | Annals of the Rheumatic Diseases | 2019 | 353 | 0 | |||
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection | European Journal of Immunology | 2018 | 343 | 0 | |||
Biological agents in the management of adult-onset Still's disease | Joint, Bone, Spine | 2018 | 371 | 226 | |||
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration | Annals of the Rheumatic Diseases | 2018 | 413 | 1 | |||
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism | Cancer Research | 2018 | 348 | 0 | |||
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries | RMD Open | 2018 | 273 | 112 | |||
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice | Blood | 2018 | 412 | 2 | |||
Regulation and function of interleukin-36 cytokines | Immunological Reviews | 2018 | 397 | 0 | |||
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study | RMD Open | 2018 | 356 | 139 | |||
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion | Cell Reports | 2018 | 549 | 233 | |||
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome | Blood | 2018 | 289 | 1 | |||
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease | Annals of the Rheumatic Diseases | 2018 | 384 | 166 | |||
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance | Frontiers in Immunology | 2018 | 331 | 180 | |||
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | 2018 | 375 | 363 | |||
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment | Small | 2018 | 573 | 356 | |||
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Swiss Medical Weekly | 2017 | 522 | 253 | |||
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis | Rheumatology | 2017 | 448 | 5 | |||
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | 2017 | 518 | 3 | |||
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition | Journal of Allergy and Clinical Immunology | 2017 | 381 | 2 | |||
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 386 | 2 | |||
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus | Autoimmunity Reviews | 2017 | 338 | 1 | |||
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials | RMD Open | 2017 | 344 | 212 | |||
Cardiovascular risk in patients with rheumatoid arthritis | Seminars in Immunopathology | 2017 | 382 | 0 | |||
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies | Seminars in Immunopathology | 2017 | 284 | 0 | |||
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis | Arthritis and Rheumatology | 2017 | 462 | 0 | |||
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration | Journal of Rheumatology | 2017 | 378 | 1 | |||
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis | PLOS ONE | 2017 | 410 | 141 | |||
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype | PloS one | 2017 | 496 | 204 | |||
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro | Annals of the Rheumatic Diseases | 2017 | 376 | 0 | |||
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab | RMD Open | 2017 | 328 | 167 | |||
The role of female hormonal factors in the development of rheumatoid arthritis | Rheumatology | 2017 | 398 | 0 | |||
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses | Journal of Immunology | 2017 | 701 | 2 | |||
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis | Arthritis & rheumatology | 2016 | 442 | 0 | |||
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease | Arthritis Research and Therapy | 2016 | 1 001 | 271 | |||
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease | Clinical and experimental immunology | 2016 | 460 | 2 | |||
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis | Annals of the rheumatic diseases | 2016 | 461 | 197 | |||
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines | Cytokine | 2016 | 456 | 1 | |||
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study | Annals of the rheumatic diseases | 2016 | 456 | 0 | |||
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis | Rheumatology | 2016 | 480 | 0 | |||
IL-1R1-MyD88 axis elicits papain-induced lung inflammation | European Journal of Immunology | 2016 | 434 | 0 | |||
IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid Cells | Journal of Immunology | 2016 | 474 | 2 | |||
Elevated serum levels of free interleukin-18 in adult-onset Still's disease | Rheumatology | 2016 | 481 | 0 | |||
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype | Journal of leukocyte biology | 2016 | 447 | 1 | |||
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration | Arthritis Research and Therapy | 2016 | 419 | 171 | |||
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice | International journal of pharmaceutics | 2016 | 814 | 4 | |||
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases | Cytokine | 2015 | 169 | 0 | |||
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection | PloS one | 2015 | 492 | 197 | |||
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | Rheumatology | 2015 | 447 | 0 | |||
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling | Immunity, inflammation and disease | 2015 | 1 124 | 167 | |||
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists | Dermatology | 2015 | 400 | 0 | |||
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33-Overexpressing CMV/IL33 Mice | The Journal of immunology | 2015 | 620 | 2 | |||
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study | Arthritis research & therapy | 2015 | 485 | 435 | |||
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study | Inflammatory bowel diseases | 2015 | 435 | 0 | |||
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system | European journal of pharmaceutics and biopharmaceutics | 2015 | 618 | 4 | |||
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics | Arthritis research & therapy | 2014 | 500 | 309 | |||
Immune-mediated experimental arthritis in IL-33 deficient mice | Cytokine | 2014 | 603 | 0 | |||
Inflammation: IL-36 has proinflammatory effects in skin but not in joints | Nature reviews. Rheumatology | 2014 | 529 | 0 | |||
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee | International orthopaedics | 2014 | 531 | 0 | |||
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs? | Journal of rheumatology | 2014 | 461 | 0 | |||
Traitement de fond de la polyarthrite rhumatoïde | Revue médicale suisse | 2014 | 231 | 2 | |||
Biological agents in monotherapy for the treatment of rheumatoid arthritis | Schweizerische medizinische Wochenschrift | 2014 | 498 | 2 | |||
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in Caucasians | Clinical immunology | 2014 | 566 | 1 | |||
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour | Annals of the rheumatic diseases | 2014 | 581 | 2 | |||
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout | Arthritis & rheumatology | 2014 | 640 | 0 | |||
The severity of experimental arthritis is independent of IL-36 receptor signaling | Arthritis research & therapy | 2013 | 580 | 216 | |||
Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions | Journal of leukocyte biology | 2013 | 486 | 463 | |||
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis" | Joint bone spine | 2013 | 510 | 0 | |||
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement | Annals of the rheumatic diseases | 2013 | 636 | 431 | |||
Hand osteoarthritis: new insights | Joint bone spine | 2013 | 542 | 0 | |||
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions | Annals of the rheumatic diseases | 2013 | 565 | 343 | |||
Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply | Lancet | 2013 | 494 | 0 | |||
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency | Arthritis research & therapy | 2013 | 586 | 237 | |||
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience | Schweizerische medizinische Wochenschrift | 2013 | 778 | 379 | |||
Do synovial leptin levels correlate with pain in end stage arthritis? | International orthopaedics | 2013 | 615 | 145 | |||
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Lancet | 2013 | 570 | 0 | |||
The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans | Frontiers in immunology | 2013 | 534 | 269 | |||
Endogenous IL-1α is a chromatin-associated protein in mouse macrophages | Cytokine | 2013 | 558 | 1 | |||
Coexistence of seropositive rheumatoid arthritis and SAPHO syndrome | Joint bone spine | 2013 | 564 | 0 | |||
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial | Annals of the rheumatic diseases | 2012 | 614 | 0 | |||
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments | Arthritis and rheumatism | 2012 | 516 | 1 | |||
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists | Annals of the rheumatic diseases | 2012 | 498 | 375 | |||
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis | Joint bone spine | 2012 | 669 | 622 | |||
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Arthritis care & research | 2012 | 641 | 0 | |||
Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitis | European Journal of Immunology | 2012 | 546 | 3 | |||
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters | Journal of leukocyte biology | 2012 | 614 | 0 | |||
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease | Arthritis research & therapy | 2012 | 630 | 321 | |||
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells | Blood | 2012 | 739 | 824 | |||
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration | Annals of the rheumatic diseases | 2012 | 549 | 1 | |||
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis | Annals of the rheumatic diseases | 2012 | 641 | 543 | |||
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients | Annals of the rheumatic diseases | 2012 | 597 | 0 | |||
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice | Annals of the rheumatic diseases | 2012 | 601 | 0 | |||
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients | Haematologica | 2011 | 955 | 555 | |||
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries | Annals of the rheumatic diseases | 2011 | 489 | 0 | |||
IL-36R ligands are potent regulators of dendritic and T cells | Blood | 2011 | 594 | 0 | |||
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infection | Microbes and infection | 2011 | 565 | 0 | |||
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center | Arthritis and rheumatism | 2011 | 551 | 0 | |||
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study | Arthritis and rheumatism | 2011 | 788 | 8 | |||